Licit and illicit substance use among persons who inject drugs and the association with subsequent suicidal attempt by Roy, Élise
 1 
Licit and illicit substance use among persons who inject drugs and the association with 
subsequent suicidal attempt  
 
Andreea Adelina Arteniea, Julie Bruneaua,b,c, Élise Royd,e, Geng Zanga, François Lespérancea,f, 
Johanne Renaudg, Joël Tremblayh, Didier Jutras-Aswada,f 
 
a Research Center, Centre Hospitalier de l’Université de Montréal (CHUM), 900 Saint-Denis, 
Montréal, QC, Canada H2X 0A9 
b Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, 
C.P. 6128, succursale Centre-ville, Montréal, QC, Canada H3C 3J7 
c Department of Family Medicine, Faculty of Medicine, McGill University, 5858 Chemin de la 
Côte-des-Neiges, Montréal, QC, Canada H3S 1Z1 
d Addiction Research and Study Program, Faculty of Medicine and Health Sciences, Université 
de Sherbrooke, 150 Place Charles-Le Moyne, Longueuil, QC, Canada J4K 0A8 
e Institut National de Santé Publique du Québec, 190 Crémazie E, Montréal, QC, Canada H2P 
1E2 
f Department of Psychiatry, Faculty of Medicine, Université de Montréal, C.P. 6128, succursale 
Centre-ville, Montréal, QC, Canada H3C 3J7 
g Department of Psychiatry, Faculty of Medicine, McGill University, 1033 Pine Avenue West, 
Montréal, QC, Canada H3A 1A1 
h Department of Psychoeducation, Université du Québec à Trois-Rivières, C.P. 500, Trois-
Rivières, QC, Canada G9A 5H7 
 
Contact information (Corresponding author): 
 2 
Didier Jutras-Aswad, MD, MSc 
Research Center, Centre Hospitalier de l’Université de Montréal (CHUM) 
Tour Viger 
900, Saint-Denis, office R06-444 
Montréal, QC, Canada 
Phone: +1 (514) 890-8000 Ext.35703             Fax:+1 (514) 412-7320 
E-mail: didier.jutras-aswad@umontreal.ca 
 
DECLARATION OF INTEREST: None 
 
 ͵
$%675$&7
$LP7RHVWLPDWHDVVRFLDWLRQVEHWZHHQUHFHQWOLFLWDQGLOOLFLWVXEVWDQFHXVHDQGVXEVHTXHQW
VXLFLGHDWWHPSWDPRQJSHUVRQVZKRLQMHFWGUXJV3:,''HVLJQ6HFRQGDU\DQDO\VLVRI
ORQJLWXGLQDOGDWDIURPDSURVSHFWLYHFRKRUWVWXG\RI3:,'IROORZHGELDQQXDOO\EHWZHHQ
DQG6HWWLQJ0RQWUpDO&DQDGD3DUWLFLSDQWV6HYHQKXQGUHGDQGQLQHW\VHYHQ3:,'
ZKRUHSRUWHGLQMHFWLRQGUXJXVHLQWKHSUHYLRXVVL[PRQWKVFRQWULEXWLQJWRDWRWDORIVWXG\
YLVLWV7KHPHGLDQQXPEHURIYLVLWVSHUSDUWLFLSDQWZDV,QWHUTXDUWLOHUDQJH
0HDVXUHPHQWV$QLQWHUYLHZHUDGPLQLVWHUHGTXHVWLRQQDLUHHOLFLWLQJLQIRUPDWLRQRQVRFLR
GHPRJUDSKLFIDFWRUVGHWDLOHGLQIRUPDWLRQRQVXEVWDQFHXVHSDWWHUQVDQGUHODWHGEHKDYLRXUV
PHQWDOKHDOWKPDUNHUVDQGVXLFLGHDWWHPSW7KHSULPDU\H[SRVXUHYDULDEOHVH[DPLQHGZHUHSDVW
PRQWKXVHRIDOFRKRO>KHDY\≥GULQNVPRGHUDWHGULQNVQRQH@VHGDWLYHK\SQRWLFV
FDQQDELVFRFDLQHDPSKHWDPLQHDQGRSLRLGV>UHJXODU≥GD\VRFFDVLRQDOGD\VQRQH@
7KHRXWFRPHZDVDELQDU\PHDVXUHRIVXLFLGHDWWHPSWDVVHVVHGLQUHIHUHQFHWRWKHSUHYLRXVVL[
PRQWKV)LQGLQJV,QPXOWLYDULDWHDQDO\VHVDSRVLWLYHDVVRFLDWLRQZDVIRXQGDPRQJOLFLW
VXEVWDQFHVEHWZHHQKHDY\DOFRKROFRQVXPSWLRQ>DGMXVWHGRGGVUDWLR$25
FRQILGHQFHLQWHUYDO&,@UHJXODUXVHRIVHGDWLYHK\SQRWLFV$25&,
±DQGVXEVHTXHQWDWWHPSWHGVXLFLGH$PRQJLOOLFLWVXEVWDQFHVRFFDVLRQDOXVHRI
FDQQDELV$25&,KDGDSRVLWLYHDVVRFLDWLRQZLWKVXEVHTXHQWVXLFLGH
DWWHPSW1RVWDWLVWLFDOO\VLJQLILFDQWDVVRFLDWLRQZDVIRXQGIRUWKHUHPDLQLQJVXEVWDQFHV
&RQFOXVLRQ$PRQJSHUVRQVZKRLQMHFWGUXJVXVHRIDOFRKROVHGDWLYHK\SQRWLFVDQGFDQQDELV
EXWQRWFRFDLQHDPSKHWDPLQHRURSLRLGVDSSHDUVWREHDVVRFLDWHGZLWKLQFUHDVHGOLNHOLKRRGRI
ODWHUDWWHPSWHGVXLFLGH
 4 
Introduction 
Suicide is a leading cause of mortality worldwide, estimated to account for more than 
800,000 deaths each year (1). Substance use is well-documented as being one of the main risk 
factors, closely following depression and other mood disorders (2, 3). In a landmark empirical 
review investigation of cohort studies, individuals with alcohol and drug use disorders were 
found to be nearly 10 and 17 times, respectively, more likely than peers to die of suicide (4).  
Among illicit drug-users, suicide is a predominant cause of mortality, accounting for an 
estimated 1 in 10 deaths (5, 6). Furthermore, studies conducted in the United States (7), Australia 
(8), Germany (9) and Brazil (10) noted lifetime prevalences of suicide attempt (SA) to be 
ranging from 20% to nearly 50% in this population. A nonfatal SA is estimated to be one of the 
most potent predictors of completed suicide (3).  
While an abundant literature has documented the high risk of suicidal behaviours among 
illicit drug users, available evidence leaves considerable uncertainty regarding the association 
between use of individual substance types and suicidality in this population (11). Studies 
assessing this relationship have relied mainly upon cross-sectional data, and reported mixed 
findings. Use of licit substances, including sedative-hypnotic drugs (9, 12) and alcohol (13) has 
been found to be positively associated with SA in some studies. Conversely, others did not find a 
significant association between SA and specific types of substances used (14, 15). Fewer 
investigations have examined this relationship prospectively. In a multi-city study of recently 
treated drug-users in the United States, individuals who reported primarily cocaine use at 
treatment entry had three-fold greater odds of indicating an episode of SA at 12-month follow-up 
(16). In a clinical sample of drug users in Boston, no statistically significant association was 
found between recent use of a specific substance and risk of SA (7). Only one study has been 
conducted among people who inject drugs (PWID) (17), despite being a population potentially at 
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greater risk of suicidal behaviours compared to non-injection drug users (18). In this seven-year 
study of community-recruited PWID in Vancouver, methamphetamine injection was found to be 
associated with an 80% increased risk of SA (17), although findings are limited by a lack of 
control for potentially important confounding factors, such as previous SA and psychiatric co-
morbidity (7). Furthermore, although use of multiple substances, including licit and illicit, is 
common among drug-using populations (19, 20), none of these three studies have concurrently 
assessed a broad range of commonly used substance types. 
More recently, in a longitudinal study conducted by our group to examine the relation 
between SA and use of specific substance types among PWID in Montréal, the likelihood of 
reporting an attempt was found to be nearly twofold greater for users of cocaine, amphetamine 
and sedative-hypnotics (21). Conversely, no statistically significant association was found 
between SA and use of opioids, cannabis and alcohol. Although this study points toward 
important markers of suicidal behaviours among PWID, the directionality of the observed 
associations was not assessed, as substance use and SA, measured at each follow-up visit, were 
examined in reference to the same time frame. Knowing whether use of specific substances is 
predictive of greater vulnerability to suicide could help to identify which subgroups of drug users 
are most at risk, and to inform the development of tailored prevention strategies. Building upon 
our previous work, the objective of this study, conducted in a sample of PWID recruited and 
followed longitudinally between 2004 and 2011 in Montréal, Canada, was to estimate the 
associations between past-month licit and illicit substance use, measured at each study visit, and 
SA reported in the following six-month period.   
Methods 
Study design and participants 
This study relied upon secondary data collected as part of the Hepatitis Cohort (HEPCO), 
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a cohort of PWID established in November 2004 in Montréal, to examine determinants of 
hepatitis C virus (HCV) transmission. A detailed description of the cohort recruitment and 
follow-up procedures has been published previously (22). In brief, to be eligible for recruitment 
into HEPCO, participants were required to be current PWID (i.e., to have injected drugs within 
the previous six months) and to be 18 years of age or older. Participants were a convenience 
sample of PWID in Montréal, recruited via different strategies, including referrals from 
community-based programs catering to the needs of PWID and word-of-mouth. At baseline and 
each six-month follow-up visit, participants completed an extensive interviewer-administered 
questionnaire, eliciting information on socio-demographic characteristics, detailed information 
on substance use patterns, and individual and contextual factors often associated with injection 
drug use. A section of the questionnaire was devoted to assessing global health, including mental 
health and SA. The interviewers and nurses working on-site offered information and referrals to 
addiction, mental health or HCV treatment services on a case-by-case basis. A CAD 20.00$ 
honorary was offered to all study participants upon completion of the questionnaire, as 
compensation for their time. Ethical approval for this study was provided through the Ethics 
Review Board of the Centre Hospitalier de l’Université de Montréal. 
Between November 2004 and March 2011, 1,240 PWID were recruited in HEPCO, 
contributing to a total of 5,621 observations. Only participants with two study visits were eligible 
for inclusion in the present study. Additionally, as the aim of this investigation was to examine 
proximal factors associated with subsequent SA, follow-up visits from participants who were 
temporarily lost to follow-up for more than one year were excluded after this gap period, even if 
they resumed their participation later on, resulting in the removal of 718 observations (12.8%). 
Thus, of the 1,240 total participants, 443 were excluded because i) they did not return for a 
follow-up visit (n= 361), and ii) their first follow-up visit had occurred more than a year after the 
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initial assessment (n=82).  
The present study included a total of 4,460 observations collected from 797 participants. 
Compared to participants who were excluded from the analyses (n=443), those who were 
included were slightly younger [median age (interquartile range (IQR))= 38.7 (29.4 - 44.9) 
versus 39.6 (31.2 – 46.7), p= 0.034], less likely to be male (82.0% versus 86.6%, p= 0.037) and 
more likely to use opioids (52.8% versus 45.3%, p= 0.013). Distributions of suicide attempt, 
education and substance use other than opioids were similar between the two groups (data not 
shown).  
Measures 
Consistent with previous studies (14, 17, 21), the outcome of interest was a dichotomous 
measure of having experienced a SA, assessed by the following question: “In the past six 
months, have you attempted suicide?”. The primary exposure variables were assessed by 
questioning participants on the types of substances consumed and associated frequency of use in 
the previous month. Six substance types that are commonly used by PWID were examined and 
included alcohol, sedative-hypnotic drugs (counting benzodiazepines and barbiturates), cannabis, 
cocaine, amphetamine and opioids (counting heroin and prescription opioids). As eligible 
participants must have injected drugs in the previous six months, cocaine, amphetamine and 
opioids were the primary drugs of abuse in our sample, whereas the remaining substances were 
typically co-used. The United States Centers for Disease Control and Prevention defines heavy 
drinking as consuming 15 and 8 drinks or more per week for men and women, respectively (23). 
Considering that the great majority of our study sample was composed of males (82.0%), heavy 
drinking was defined as having consumed 60 drinks or more in the past month, and moderate 
drinking as having consumed from one to 59 drinks. A third category, no alcohol consumption, 
was also included. Frequency of drug use was classified as regular, occasional or none, based on 
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the number of days of use in the previous month. In line with the definitions used by the United 
States Office of National Drug Control Policy (24), regular drug use was defined as having 
consumed on four days or more in the previous month, and occasional use as having consumed 
from one to three days over the same time period. Similar definitions have been used previously 
to describe frequencies of drug use among illicit drug-using populations (7, 25).  
Potential confounders included measured variables identified previously as important 
correlates of SA among drug users (7, 14, 17, 21). Socio-demographic characteristics included 
age, gender and education. Markers of psychosocial stress potentially associated with SA 
included identifying with a sexual minority group (gay, lesbian or bisexual versus heterosexual), 
living in unstable housing conditions and having been incarcerated in the previous six months. 
Consistent with previous studies (22), unstable housing was defined as living on the street, in 
shelters or in apartment-hotels rented on a monthly basis, indicating rapid turnover compared to 
typical 12-month rent–lease accommodation standards in Montréal. Participants were also asked 
whether they received treatment for anxiety or depression in the previous six months and 
whether they have ever been diagnosed with a mental disorder. Because information on prior 
attempted suicide (lifetime) was not recorded in our study, SA measured at the first study visit, 
with reference to the previous six months, was examined as an indicator of prior attempt. This 
variable appears to be a good proxy measure for prior SA, as the risk of a repeat attempt is 
estimated to be highest in the first six months following an index attempt (26, 27). A follow-up 
time variable indicating number of visits since baseline assessment was also included to control 
for different follow-up durations among participants.  
Statistical analyses  
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Descriptive statistics were used to characterise the study population at baseline 
assessment and included frequency distributions for categorical variables, and median and 
corresponding IQR for the continuous variable age.  
The incidence of SA was calculated using the person-time method, and 95% confidence 
intervals (CI) were estimated using the Poisson distribution. The date of SA was estimated to 
have occurred at the midpoint between the last visit at which no SA was reported and the visit 
with the first report of SA. Participants were right censored at the date of their first SA, or at 
their last study visit if no SA was reported.  
Generalized estimating equation (GEE) analyses with a binomial logit link function and 
autoregressive order 1 covariance structure (28, 29) were used to examine the relationship 
between substance use and SA throughout the entire 77–month period, while accounting for 
within-subject correlation as a result of repeated measurements made for participants with 
multiple assessments. To examine whether substance use was associated with subsequent SA, the 
outcome variable was selected from the interview immediately following that of the exposure 
variables. GEE models provide population-averaged estimates of parameters (30). In our study, 
odds ratios derived from the GEE analyses are interpreted as the averaged odds of reporting a SA 
for PWID indicating use of a certain substance compared to the averaged odds of reporting a SA 
for PWID who did not indicate use of that substance. 
Univariate GEE analyses were conducted to calculate odds ratios and corresponding 95% 
CI for the associations between substance use, potential confounding variables and subsequent 
SA. In order to adjust for possible confounding, two multivariate models were constructed: a full 
model, including all variables of interest, and a reduced model containing only those that 
remained associated significantly with SA. Starting with the full model considering all variables, 
the reduced model was fitted using a backward selection procedure.  Using an a priori-defined 
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model building protocol, basic socio-demographic characteristics (age and gender) were retained 
in the final model. With the exception of age, gender and previous SA, exposure variables were 
treated as time-dependent, representing their most recent value. For all analyses, p-values were 
two-sided, with p<0.05 used as a criterion for statistical significance. Statistical analyses were 
performed using SAS 9.3 software (SAS Institute, Cary, NC, USA).   
 Results 
Table 1 presents the characteristics of the 797 PWID forming the study sample at 
baseline assessment. Their median age was 38.7 (IQR: 29.4 - 44.9) and the majority (82.0%) was 
male. Approximately two-thirds of participants reported using alcohol and cannabis, and one-
third indicated using sedative-hypnotics. Cocaine use was reported by the majority of 
participating PWID and use of opioids by approximately half. Only a minority indicated using 
amphetamine. A considerable proportion of participating PWID presented markers of 
psychosocial stress. For instance, nearly half reported living in unstable housing conditions and 
one in three had a history of a diagnosed mental disorder. Forty-eight participants (6.0%) 
reported a SA in the previous six months.  
 
During the 77-month follow-up period, the mean and median number of study visits per 
participant was 5.6 (standard deviation: 3.3) and 5 (IQR: 3 – 8) respectively. The median time 
between consecutive visits was 5.9 months (IQR: 5.3 – 6.5). Besides for the SA reported at 
baseline assessment, a total of 115 SA were reported during follow-up by 70 (8.8%) participants. 
Among participants who experienced a SA, the median number of SA during follow-up was 1 
(IQR: 1 - 2). During 2347.92 person-years of follow-up, a total of 96 first SA events were 
reported, yielding an overall incidence rate of 4.09 per 100 person-years (95% CI: 3.33 – 4.97).  
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Results from the GEE analyses of factors associated with SA are presented in Table 2. In 
univariate analyses, among licit substances, a statistically significant positive association was 
found between heavy and moderate alcohol consumption, regular and occasional sedative-
hypnotics use and subsequent SA. Among illicit substances, only occasional cannabis use had a 
statistically significant positive association with subsequent SA. In multivariate analyses 
(reduced model), the positive associations between heavy alcohol consumption [Adjusted odds 
ratio (AOR): 2.05; 95% CI: 1.12 - 3.75), regular sedative-hypnotics use (AOR: 1.89; 95% CI: 
1.21 - 2.95), occasional cannabis use (AOR: 1.84; 95% CI: 1.09 -3.13) and later SA persisted. 
Other factors that remained independently associated with later SA were prior SA, history of a 
diagnosed mental disorder and follow-up time.   
 
Discussion  
Our study indicates that PWID in Montréalare at high risk of suicidal behaviours. At 
baseline assessment, 6.0% of participants reported having experienced an episode of SA in the 
previous six-month period, similar to prevalences reported previously in community samples of 
PWID in Vancouver (17) and in the United States (14). The incidence of SA was also high, 
estimated at 4.1 per 100 person-years, slightly higher than the rate reported among PWID in 
Vancouver (2.5 per 100 person-years) (17). The main finding of our study is that recent use of 
alcohol, sedative-hypnotics and cannabis is, by and large, associated with subsequent SA among 
PWID. Conversely, use of cocaine, amphetamine or opioids is not associated with later SA.  
Among illicit drug-using populations, including PWID, use alcohol, sedative-hypnotic 
drugs and cannabis is typically nested in a broader pattern of polysubstance use involving hard 
drugs, notably cocaine, amphetamine and opioids, which are generally the primary drugs of 
abuse. Our findings suggest that use of primary drugs may not play a direct role in shaping 
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vulnerability to subsequent SA in this population. Rather, suicidal behaviours appear to be 
closely linked with substances that are typically co-used alongside primary drugs. To our 
knowledge, this study is the first to examine prospectively the temporal relationship between a 
broad range of commonly used substance types and SA in a population of illicit drug users. 
Differences in findings with respect to our previous study (21), which reported a positive 
association between use of cocaine, amphetamine and SA, could suggest that PWID who engage 
in suicidal behaviours turn to stimulants to escape feelings of anhedonia or depression (31). It is 
also possible that this association is mediated by factors that are associated with both stimulant 
use and SA, such as impulsivity (32, 33).  
The direct physiologic and behavioural effects of alcohol, sedative-hypnotics and 
cannabis, particularly if used in the context of polysubstance use, are likely to account for our 
findings. Alcohol dependence and associated psychiatric comorbidity has been proposed to act as 
a distal risk factor for suicidal behaviours, elevating susceptibility over time (34). Moreover, 
alcohol intoxication can lead to increased impulsivity and depressive thoughts, enhanced 
behavioural disinhibition and narrowed attention, thereby also acting as a proximal risk factor for 
suicidality (34). Paradoxically, the use of sedative-hypnotic drugs, particularly benzodiazepines, 
has also been reported to induce depressive thoughts and enhance behavioural disinhibition in 
certain individuals (5-10%), leading to increased vulnerability to taking action on suicidal 
thoughts (35, 36). Although cannabis has been associated with increased suicidal behaviours in 
some studies, meaningful evidence supporting this association is currently lacking, as is 
knowledge of the potential mechanisms that may underlie it (37). Further research examining the 
role of cannabis use in relation to suicidal behaviours is needed.  
The greater odds of reporting a SA among participants indicating use of alcohol, 
sedative-hypnotic drugs and cannabis may also be reflective of a sub-group of PWID who is 
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experiencing greater psychological distress and is therefore, more susceptible to suicidal 
behaviours. Use of these drugs may be an attempt at self-medication (38, 39). Although, in our 
analyses, we accounted for the presence of a diagnosed mental disorder and recent treatment for 
anxiety or depression, PWID could be self-medicating conditions that have never received 
medical attention.  
Although alcohol, benzodiazepines and cannabis are frequently co-used among street-
based illicit drug users, these substances do not typically make up a predominant focus of 
prevention messages in this group, as their associated problems may be considered secondary to 
those engendered by the use of hard drugs. However, aside for the evidence implicating use of 
these soft drugs and of alcohol in suicidal behaviours, their use has been linked previously with 
risky injection and sexual practices (40, 41), unintentional overdose (42), relapse to drug use (43) 
and accelerated course of chronic Hepatitis C development among HCV-infected drug users 
(44). These findings highlight a need to systematically screen for, and address the use of such 
substances among PWID. Although limited, research has indicated that relatively simple 
interventions, such as brief motivational counselling, can have positive impacts on patterns of 
alcohol use among PWID (45). Similar models could be employed to address the use of sedative-
hypnotics and cannabis.  
As reported previously (7, 16), a prior SA was a strong correlate of later attempt in our 
study. In addition, a history of a mental disorder was independently associated with subsequent 
SA, similar to findings reported in prior studies of drug-using populations (7, 12). PWID 
frequently experience psychological distress and mental health problems (46). Nearly one third 
of participants in our study reported a history of a diagnosed mental disorder. Altogether, these 
findings further support the need for enhanced linkage between addiction treatment, mental 
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health and community-based programs in order to promote timely identification, assessment and 
management of PWID at risk of engaging in suicidal behaviours. 
Our study presents a number of limitations. As with most studies involving illicit drug-
using populations, the HEPCO cohort is not a random sample, thereby limiting the 
generalisability of our findings. However, aside for being fairly older, the socio-demographic 
and substance use characteristics of participants are, by and large, reflective of the PWID 
population in Québec (47). Even though our follow-up rate is high for a drug-using population 
and few differences were found between participants who did and did not return for a follow-up 
assessment, it is possible that our data may have been influenced by losses to follow-up. 
As this investigation relied on self-reported data, findings are subject to social desirability 
bias, although self-reported data collected from drug-using populations appear to be generally 
valid (48). Information on prior SA (lifetime) and other factors possibly linked to SA such as 
stressful life events and family history of suicide (49) was not collected, making residual 
confounding of our findings a possibility. However, we attempted to address the former 
limitation by considering SA reported at baseline assessment as a proxy measure of prior SA. 
Additionally, details regarding the methods used to attempt suicide were not measured, thus 
limiting our ability to examine associations between substance use and different types of SA. 
Although different frequencies of substance use were examined in order to distinguish between 
different severities of substance use, this study did not measure alcohol and drug disorders based 
on criteria from the Diagnostic and Statistical Manual of Mental Disorders, which may be more 
strongly associated with SA compared to substance use. On a similar note, while our analyses 
controlled for markers of psychological distress, mental health was not assessed using validated 
instruments. Lastly, given the observational nature of our study, causal inferences regarding the 
association between substance use and SA cannot be drawn. Although our methodological 
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approach, modelling SA as a time-lagged outcome, attempts to tease out the direction of the 
association, a reverse association between substance use and SA cannot be ruled completely out, 
nor can a bidirectional relation (50). 
Notwithstanding these limitations, our study provides important insights regarding the 
relationship between recent licit and illicit substance use and subsequent SA among PWID. 
Findings suggest that, use of alcohol, sedative-hypnotics and cannabis, substances that are 
typically co-used among illicit drug-users, are associated with increased odds of reporting a later 
SA. Although additional research is needed to understand the nature of these associations, 
findings highlight the importance of addressing use of alcohol and soft drugs as part of suicide 
prevention efforts among PWID.  
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Table 1: Baseline characteristics of 797 people who inject drugs recruited between November 
2004 and March 2011 in the HEPCO cohort in Montréal, Canada 
Characteristic Category n (%) 
Age Median (IQR) 38.7 (29.4 – 44.9) 
Male 653 (82.0) Gender 
Female 143 (18.0) 
Yes 475 (59.7) Completed high-school education 
No 321 (40.3) 
Heavy 259 (32.8) 
Moderate 314 (39.8) 
Alcohol use+ 
None 216 (27.4) 
Regular 186 (23.8) 
Occasional 83 (10.6) 
Sedative-hypnotics use+ 
None 514 (65.6) 
Regular 420 (53.3) 
Occasional 109 (13.8) 
Cannabis use+ 
None 259 (32.9) 
Regular 472 (60.8) 
Occasional 151 (19.5) 
Cocaine use+ 
None 153 (19.7) 
Regular 21 (2.7) 
Occasional 44 (5.6) 
Amphetamine use+ 
None 720 (91.7) 
Regular 317 (40.7) 
Occasional 94 (12.1) 
Opioids use+ 
None 368 (47.2) 
Yes 542 (68.3) Cocaine injection+ 
No 251 (31.7) 
Yes 7 (0.9) Amphetamine injection+ 
No  790 (99.1) 
Yes 374 (47.0) Opioids injection+ 
No 422 (53.0) 
LGB 100 (12.7) Sexual orientation+ 
Heterosexual 690 (87.3) 
Yes 333 (41.8) Unstable housing++ 
No  463 (58.2) 
Yes 173 (21.8) Incarceration++ 
No  621 (78.2) 
Yes 212 (26.6) Treatment for anxiety or depression++ 
No  585 (73.4) 
Yes 249 (31.3) History of a diagnosed mental 
disorder No  546 (68.7) 
Yes 48 (6.0) Suicide attempt++ 
No 749 (94.0) 
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Abbreviations: IQR, interquartile range; LGB, lesbian, gay or bisexual 
+Denotes activity in the past month; ++Denotes activity in the past six months 
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Table 2: Generalized estimating equation analyses of factors associated with suicide attempt 
among 797 people who inject drugs participating in a prospective cohort in Montréal, Canada, 
between November 2004 and March 2011 (N=4,460 observations) 
Adjusted OR (95% CI) 
 
Characteristic 
  
 
Category 
  
 
Unadjusted OR  
(95% CI) 
  Full model Reduced model 
Age 5-year 
increase 
0.91 (0.79 - 1.06) 0.90 (0.76 - 1.08) 0.94 (0.79 - 1.11) 
Male 0.42 (0.23 - 0.76)** 0.66 (0.31 - 1.40) 0.59 (0.31 - 1.13) Gender 
Female Ref Ref Ref 
Yes 0.97 (0.61 - 1.54) 0.88 (0.53 - 1.44)   Completed high-
school education No Ref Ref   
Heavy 2.33 (1.27 - 4.29)** 2.19 (1.16 - 4.13)* 2.05 (1.12 - 3.75)* 
Moderate 1.74 (1.02 - 2.95)* 1.50 (0.87 - 2.59) 1.60 (0.94 - 2.72) 
Alcohol use+ 
None Ref Ref   
Regular 2.62 (1.70 - 4.03)** 1.71 (1.03 - 2.82)* 1.89 (1.21 - 2.95)** 
Occasional 2.15 (1.21 - 3.80)** 1.62 (0.86 - 3.04) 1.60  (0.85 - 2.98) 
Sedative-hypnotics 
use+ 
None Ref Ref   
Regular 1.20 (0.73 - 1.98) 1.16 (0.68 - 1.96) 1.17 (0.68 -1.99) 
Occasional 1.90 (1.17 - 3.07)** 2.04 (1.21 - 3.45)** 1.84 (1.09 -3.13)* 
Cannabis use+ 
None Ref Ref   
Regular 1.10 (0.67 - 1.81) 0.91 (0.52 - 1.60)   
Occasional 1.09 (0.62 - 1.93) 1.08 (0.58 - 2.00)   
Cocaine use+ 
None  Ref Ref   
Regular 1.12 (0.42 - 3.01) 0.63 (0.16 - 2.41)   
Occasional 0.31 (0.06 - 1.54) 0.25 (0.06 - 1.10)   
Amphetamine use+ 
None  Ref Ref   
Regular 1.13 (0.72 - 1.75) 0.86 (0.52 - 1.42)   
Occasional 1.13 (0.61 - 2.08) 0.91 (0.46 - 1.81)   
Opioids use+ 
None  Ref Ref   
LGB 2.30 (1.14 - 4.64)* 1.19 (0.51 - 2.75)   Sexual orientation 
Heterosexual Ref Ref   
Yes 0.87  (0.56 - 1.34) 0.88 (0.52 - 1.48)   Unstable housing++ 
No  Ref Ref   
Yes 0.84 (0.49 - 1.44) 1.09 (0.64 - 1.88)   Incarceration++ 
No  Ref Ref   
Yes 2.23 (1.36 - 3.63)** 1.35 (0.78 - 2.32)   Treatment for 
anxiety or 
depression++ 
No  Ref Ref   
Yes 2.73 (1.70 - 4.39)** 1.75 (1.01 - 3.04)* 1.87 (1.10 - 3.19)* History of a 
diagnosed mental 
disorder 
No  Ref Ref Ref 
Yes 9.28 (4.98 - 17.28)** 6.98 (3.71 - 13.16)** 7.43 (3.99 - 13.86)** Prior suicide 
attempt a No  Ref Ref Ref 
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Follow-up time 1-visit 
increase 
0.87 (0.80 - 0.95)** 0.89 (0.80 - 0.98)* 0.88 (0.79 - 0.97)** 
 
Abbreviations: OR, odds ratio; CI, confidence interval; LGB, lesbian, gay or bisexual 
+Denotes activity in the past month; ++Denotes activity in the past six months 
